Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

35.44 +0.15 (+0.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
The U.S. 
Via Benzinga
Exposures Product Safety
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
The three companies are spending big on IBD therapies. 
Via The Motley Fool
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
The market's dour reaction to Roivant Sciences' latest deal doesn't add up. 
Via The Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates. 
Via InvestorPlace
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases. 
Via Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
Roche Holding AG (OTC: RHHBY) inked a deal to acquire  
Via Benzinga
Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant
From Roivant Sciences
Via GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance
The company's third-quarter sales also declined and came in light. 
Via Investor's Business Daily
Exposures COVID-19
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
Roche Holdings AG's (OTC: RHHBY) nine months  
Via Benzinga
Exposures COVID-19
Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:  
Via Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing... 
Via Benzinga
Exposures Product Safety
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale. 
Via Benzinga
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
Broadcom and Arista lead five stocks sporting a flat base. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis
From Genentech
Via Business Wire
New Data for Genentech’s Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided
From Genentech
Via Business Wire
TPST Stock: 7 Things to Know About Tempest Therapeutics
Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock. 
Via InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are... 
Via Benzinga
Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions
From Genentech
Via Business Wire
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech’s Ocrevus Effectively Manages Disease Activity
From Genentech
Via Business Wire
Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
From Genentech
Via Business Wire
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c 
Via Benzinga
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
From Genentech
Via Business Wire
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich. 
Via InvestorPlace
2 Cathie Wood Stocks That Could Deliver Exponential Returns
These two cutting-edge healthcare companies could be significantly undervalued right now. 
Via The Motley Fool
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
From Genentech
Via Business Wire
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback